iNOS as a therapeutic target for treatment of human tumors

Nitric Oxide - Biology and Chemistry

Volumn 19, Issue 2, 2008, Pages 217-224

  Fitzpatrick, Brian ^a   Mehibel, Manal ^a   Cowen, Rachel L ^a   Stratford, Ian J ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Bioreductive drugs; Cancer; HIF 1; Hypoxia; Nitric oxide; Nitric oxide synthase; Radiation

Indexed keywords

1,4 BIS[[2 (DIMETHYLAMINO N OXIDE)ETHYL]AMINO] 5,8 DIHYDROXYANTHRAQUINONE; CYTOCHROME P450 REDUCTASE; HYPOXIA INDUCIBLE FACTOR 1; INDUCIBLE NITRIC OXIDE SYNTHASE; MITOXANTRONE; NITRIC OXIDE; OXIDOREDUCTASE; OXYGENASE; TIRAPAZAMINE;

CANCER GENE THERAPY; CANCER THERAPY; CYTOTOXICITY; ENZYME INHIBITION; GENE INDUCTION; GENE OVEREXPRESSION; HUMAN; HYPOXIC CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN TARGETING; RADIOSENSITIVITY; REVIEW; SEQUENCE HOMOLOGY;

ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; NEOPLASMS; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; OXIDOREDUCTASES;

EID: 47049086448     PISSN: 10898603     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.niox.2008.05.001     Document Type: Review

References (112)

1. Hemmens B., and Mayer B. Enzymology of nitric oxide synthases. Methods Mol. Biol. 100 (1998) 1-32
2. Bredt D.S., Hwang P.M., Glatt C.E., Lowenstein C., Reed R.R., and Snyder S.H. Cloned and expressed nitric oxide synthase structurally resembles cytochrome P-450 reductase. Nature 351 (1991) 714-718
3. Griffith O.W., and Stuehr D.J. Nitric oxide synthases: properties and catalytic mechanism. Annu. Rev. Physiol. 57 (1995) 707-736
4. Nathan C., and Xie Q.W. Regulation of biosynthesis of nitric oxide. J. Biol. Chem. 269 (1994) 13725-13728
5. Stuehr D.J. Structure-function aspects in the nitric oxide synthases. Annu. Rev. Pharmacol. Toxicol. 37 (1997) 339-359
6. Alderton W.K., Cooper C.E., and Knowles R.G. Nitric oxide synthases: structure, function and inhibition. Biochem. J. 357 (2001) 593-615
7. Xie Q.W., Cho H.J., Calaycay J., Mumford R.A., Swiderek K.M., Lee T.D., Ding A., Troso T., and Nathan C. Cloning and characterization of inducible nitric oxide synthase from mouse macrophages. Science 256 (1992) 225-228
8. Crowell J.A., Steele V.E., Sigman C.C., and Fay J.R. Is inducible nitric oxide synthase a target for chemoprevention?. Mol. Cancer Ther. 2 (2003) 815-823
9. Andrew P.J., and Mayer B. Enzymatic function of nitric oxide synthases. Cardiovasc. Res. 43 (1999) 521-531
10. Iida S., Ohshima H., Oguchi S., Hata T., Suzuki H., Kawasaki H., and Esumi H. Identification of inducible calmodulin-dependent nitric oxide synthase in the liver of rats. J. Biol. Chem. 267 (1992) 25385-25388
11. Palmer R.M., Andrews T., Foxwell N.A., and Moncada S. Glucocorticoids do not affect the induction of a novel calcium-dependent nitric oxide synthase in rabbit chondrocytes. Biochem. Biophys. Res. Commun. 188 (1992) 209-215
12. Radomski M.W., Jenkins D.C., Holmes L., and Moncada S. Human colorectal adenocarcinoma cells: differential nitric oxide synthesis determines their ability to aggregate platelets. Cancer Res. 51 (1991) 6073-6078
13. Saura M., Zaragoza C., Bao C., McMillan A., and Lowenstein C.J. Interaction of interferon regulatory factor-1 and nuclear factor kappaB during activation of inducible nitric oxide synthase transcription. J. Mol. Biol. 289 (1999) 459-471
14. Martin E., Nathan C., and Xie Q.W. Role of interferon regulatory factor 1 in induction of nitric oxide synthase. J. Exp. Med. 180 (1994) 977-984
15. Kamijo R., Harada H., Matsuyama T., Bosland M., Gerecitano J., Shapiro D., Le J., Koh S.I., Kimura T., Green S.J., et al. Requirement for transcription factor IRF-1 in NO synthase induction in macrophages. Science 263 (1994) 1612-1615
16. Tendler D.S., Bao C., Wang T., Huang E.L., Ratovitski E.A., Pardoll D.A., and Lowenstein C.J. Intersection of interferon and hypoxia signal transduction pathways in nitric oxide-induced tumor apoptosis. Cancer Res. 61 (2001) 3682-3688
17. Rockwell S., and Moulder J.E. Hypoxic fractions of human tumors xenografted into mice: a review. Int. J. Radiat. Oncol. Biol. Phys. 19 (1990) 197-202
18. Chapman J.D. Measurement of tumor hypoxia by invasive and non-invasive procedures: a review of recent clinical studies. Radiother. Oncol. 20 Suppl. 1 (1991) 13-19
19. Melillo G., Musso T., Sica A., Taylor L.S., Cox G.W., and Varesio L. A hypoxia-responsive element mediates a novel pathway of activation of the inducible nitric oxide synthase promoter. J. Exp. Med. 182 (1995) 1683-1693
20. Cobbs C.S., Brenman J.E., Aldape K.D., Bredt D.S., and Israel M.A. Expression of nitric oxide synthase in human central nervous system tumors. Cancer Res. 55 (1995) 727-730
21. Gallo O., Masini E., Morbidelli L., Franchi A., Fini-Storchi I., Vergari W.A., and Ziche M. Role of nitric oxide in angiogenesis and tumor progression in head and neck cancer. J. Natl. Cancer Inst. 90 (1998) 587-596
22. Swana H.S., Smith S.D., Perrotta P.L., Saito N., Wheeler M.A., and Weiss R.M. Inducible nitric oxide synthase with transitional cell carcinoma of the bladder. J. Urol. 161 (1999) 630-634
23. Song Z.J., Gong P., and Wu Y.E. Relationship between the expression of iNOS,VEGF,tumor angiogenesis and gastric cancer. World J. Gastroenterol. 8 (2002) 591-595
24. Lagares-Garcia J.A., Moore R.A., Collier B., Heggere M., Diaz F., and Qian F. Nitric oxide synthase as a marker in colorectal carcinoma. Am. Surg. 67 (2001) 709-713
25. Thomsen L.L., Miles D.W., Happerfield L., Bobrow L.G., Knowles R.G., and Moncada S. Nitric oxide synthase activity in human breast cancer. Br. J. Cancer 72 (1995) 41-44
26. Chinje E.C., Williams K.J., Telfer B.A., Wood P.J., van der Kogel A.J., and Stratford I.J. 17beta-Oestradiol treatment modulates nitric oxide synthase activity in MDA231 tumour with implications on growth and radiation response. Br. J. Cancer 86 (2002) 136-142
27. Amellem O., and Pettersen E.O. Cell inactivation and cell cycle inhibition as induced by extreme hypoxia: the possible role of cell cycle arrest as a protection against hypoxia-induced lethal damage. Cell Prolif. 24 (1991) 127-141
28. Durand R.E. The influence of microenvironmental factors during cancer therapy. In Vivo 8 (1994) 691-702
29. Davis A.J., and Tannock I.F. Tumor physiology and resistance to chemotherapy: repopulation and drug penetration. Cancer Treat. Res. 112 (2002) 1-26
30. Comerford K.M., Wallace T.J., Karhausen J., Louis N.A., Montalto M.C., and Colgan S.P. Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. Cancer Res. 62 (2002) 3387-3394
31. Teicher B.A. Hypoxia and drug resistance. Cancer Metastasis Rev. 13 (1994) 139-168
32. Erler J.T., Cawthorne C.J., Williams K.J., Koritzinsky M., Wouters B.G., Wilson C., Miller C., Demonacos C., Stratford I.J., and Dive C. Hypoxia-mediated down-regulation of Bid and Bax in tumors occurs via hypoxia-inducible factor 1-dependent and -independent mechanisms and contributes to drug resistance. Mol. Cell Biol. 24 (2004) 2875-2889
33. Huang L.E., Bindra R.S., Glazer P.M., and Harris A.L. Hypoxia-induced genetic instability--a calculated mechanism underlying tumor progression. J. Mol. Med. 85 (2007) 139-148
34. Gray L.H., Conger A.D., Ebert M., Hornsey S., and Scott O.C. The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br. J. Radiol. 26 (1953) 638-648
35. Brown J.M., and Wilson W.R. Exploiting tumour hypoxia in cancer treatment. Nat. Rev. Cancer 4 (2004) 437-447
36. Brown J.M. The hypoxic cell: a target for selective cancer therapy-eighteenth Bruce F. Cain Memorial Award lecture. Cancer Res. 59 (1999) 5863-5870
37. Brizel D.M., Sibley G.S., Prosnitz L.R., Scher R.L., and Dewhirst M.W. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int. J. Radiat. Oncol. Biol. Phys. 38 (1997) 285-289
38. Fyles A.W., Milosevic M., Wong R., Kavanagh M.C., Pintilie M., Sun A., Chapman W., Levin W., Manchul L., Keane T.J., and Hill R.P. Oxygenation predicts radiation response and survival in patients with cervix cancer. Radiother. Oncol. 48 (1998) 149-156
39. Knocke T.H., Weitmann H.D., Feldmann H.J., Selzer E., and Potter R. Intratumoral pO2-measurements as predictive assay in the treatment of carcinoma of the uterine cervix. Radiother. Oncol. 53 (1999) 99-104
40. Brizel D.M., Dodge R.K., Clough R.W., and Dewhirst M.W. Oxygenation of head and neck cancer: changes during radiotherapy and impact on treatment outcome. Radiother. Oncol. 53 (1999) 113-117
41. Lin A.J., Cosby L.A., Shansky C.W., and Sartorelli A.C. Potential bioreductive alkylating agents. 1. Benzoquinone derivatives. J. Med. Chem. 15 (1972) 1247-1252
42. Kennedy K.A., Teicher B.A., Rockwell S., and Sartorelli A.C. The hypoxic tumor cell: a target for selective cancer chemotherapy. Biochem. Pharmacol. 29 (1980) 1-8
43. McKeown S.R., Cowen R.L., and Williams K.J. Bioreductive drugs: from concept to clinic. Clin. Oncol. (R. Coll. Radiol) 19 (2007) 427-442
44. Jaffar M., Williams K.J., and Stratford I.J. Bioreductive and gene therapy approaches to hypoxic diseases. Adv. Drug Deliv. Rev. 53 (2001) 217-228
45. Zeman E.M., Brown J.M., Lemmon M.J., Hirst V.K., and Lee W.W. SR-4233: a new bioreductive agent with high selective toxicity for hypoxic mammalian cells. Int. J. Radiat. Oncol. Biol. Phys. 12 (1986) 1239-1242
46. Brown J.M. SR 4233 (tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours. Br. J. Cancer 67 (1993) 1163-1170
47. Rauth A.M., Mohindra J.K., and Tannock I.F. Activity of Mitomycin C for Aerobic and Hypoxic Cells in Vitro and in Vivo. Cancer Res. 43 (1983) 4154-4158
48. Rockwell S., Kennedy K.A., and Sartorelli A.C. Mitomycin-C as a prototype bioreductive alkylating agent: in vitro studies of metabolism and cytotoxicity. Int. J. Radiat. Oncol. Biol. Phys. 8 (1982) 753-755
49. Baker M.A., Zeman E.M., Hirst V.K., and Brown J.M. Metabolism of SR 4233 by Chinese hamster ovary cells: basis of selective hypoxic cytotoxicity. Cancer Res. 48 (1988) 5947-5952
50. Peters K.B., and Brown J.M. Tirapazamine: a hypoxia-activated topoisomerase II poison. Cancer Res. 62 (2002) 5248-5253
51. Patterson A.V., Saunders M.P., Chinje E.C., Talbot D.C., Harris A.L., and Strafford I.J. Overexpression of human NADPH:cytochrome c (P450) reductase confers enhanced sensitivity to both tirapazamine (SR 4233) and RSU 1069. Br. J. Cancer 76 (1997) 1338-1347
52. Garner A.P., Paine M.J., Rodriguez-Crespo I., Chinje E.C., Ortiz De M.P., Stratford I.J., Tew D.G., and Wolf C.R. Nitric oxide synthases catalyze the activation of redox cycling and bioreductive anticancer agents. Cancer Res. 59 (1999) 1929-1934
53. Chinje E.C., Cowen R.L., Feng J., Sharma S.P., Wind N.S., Harris A.L., and Stratford I.J. Non-nuclear localized human NOSII enhances the bioactivation and toxicity of tirapazamine (SR4233) in vitro. Mol. Pharmacol. 63 (2003) 1248-1255
54. Saunders M.P., Patterson A.V., Chinje E.C., Harris A.L., and Stratford I.J. NADPH:cytochrome c (P450) reductase activates tirapazamine (SR4233) to restore hypoxic and oxic cytotoxicity in an aerobic resistant derivative of the A549 lung cancer cell line. Br. J. Cancer 82 (2000) 651-656
55. Dorie M.J., and Brown J.M. Tumor-specific, schedule-dependent interaction between tirapazamine (SR 4233) and cisplatin. Cancer Res. 53 (1993) 4633-4636
56. Siemann D.W., and Hinchman C.A. Potentiation of cisplatin activity by the bioreductive agent tirapazamine. Radiother. Oncol. 47 (1998) 215-220
57. Dorie M.J., and Brown J.M. Modification of the antitumor activity of chemotherapeutic drugs by the hypoxic cytotoxic agent tirapazamine. Cancer Chemother. Pharmacol. 39 (1997) 361-366
58. Marcu L., and Olver I. Tirapazamine: from bench to clinical trials. Curr. Clin. Pharmacol. 1 (2006) 71-79
59. Rischin D., Peters L., Fisher R., Macann A., Denham J., Poulsen M., Jackson M., Kenny L., Penniment M., Corry J., Lamb D., and McClure B. Tirapazamine, Cisplatin, and Radiation versus Fluorouracil, Cisplatin, and Radiation in patients with locally advanced head and neck cancer: a randomized phase II trial of the Trans-Tasman Radiation Oncology Group (TROG 98.02). J. Clin. Oncol. 23 (2005) 79-87
60. Patterson L.H. Rationale for the use of aliphatic N-oxides of cytotoxic anthraquinones as prodrug DNA binding agents: a new class of bioreductive agent. Cancer Metastasis Rev. 12 (1993) 119-134
61. Patterson L.H., and McKeown S.R. AQ4N: a new approach to hypoxia-activated cancer chemotherapy. Br. J. Cancer 83 (2000) 1589-1593
62. Wilson W.R., Denny W.A., Pullen S.M., Thompson K.M., Li A.E., Patterson L.H., and Lee H.H. Tertiary amine N-oxides as bioreductive drugs: DACA N-oxide, nitracrine N-oxide and AQ4N. Br. J. Cancer Suppl. 27 (1996) S43-S47
63. Smith P.J., Blunt N.J., Desnoyers R., Giles Y., and Patterson L.H. DNA topoisomerase II-dependent cytotoxicity of alkylaminoanthraquinones and their N-oxides. Cancer Chemother. Pharmacol. 39 (1997) 455-461
64. Smith P.J., Desnoyers R., Blunt N., Giles Y., Patterson L.H., and Watson J.V. Flow cytometric analysis and confocal imaging of anticancer alkylaminoanthraquinones and their N-oxides in intact human cells using 647-nm krypton laser excitation. Cytometry 27 (1997) 43-53
65. Robson T., Worthington J., McKeown S.R., and Hirst D.G. Radiogenic therapy: novel approaches for enhancing tumor radiosensitivity. Technol. Cancer Res. Treat. 4 (2005) 343-361
66. Howard-Flanders P. Effect of nitric oxide on the radiosensitivity of bacteria. Nature 180 (1957) 1191-1192
67. Gray L.H., Green F.O., and Hawes C.A. Effect of nitric oxide on the radiosensitivity of tumour cells. Nature 182 (1958) 952-953
68. Dewey D.L. Effect of oxygen and nitric oxide on the radio-sensitivity of human cells in tissue culture. Nature 186 (1960) 780-782
69. Mitchell J.B., Cook J.A., Krishna M.C., DeGraff W., Gamson J., Fisher J., Christodoulou D., and Wink D.A. Radiation sensitisation by nitric oxide releasing agents. Br. J. Cancer Suppl. 27 (1996) S181-S184
70. Mitchell J.B., DeGraff W., Kim S., Cook J.A., Gamson J., Christodoulou D., Feelisch M., and Wink D.A. Redox generation of nitric oxide to radiosensitize hypoxic cells. Int. J. Radiat. Oncol. Biol. Phys. 42 (1998) 795-798
71. Mitchell J.B., Wink D.A., DeGraff W., Gamson J., Keefer L.K., and Krishna M.C. Hypoxic mammalian cell radiosensitization by nitric oxide. Cancer Res. 53 (1993) 5845-5848
72. Griffin R.J., Makepeace C.M., Hur W.J., and Song C.W. Radiosensitization of hypoxic tumor cells in vitro by nitric oxide. Int. J. Radiat. Oncol. Biol. Phys. 36 (1996) 377-383
73. Wardman P., Rothkamm K., Folkes L.K., Woodcock M., and Johnston P.J. Radiosensitization by nitric oxide at low radiation doses. Radiat. Res. 167 (2007) 475-484
74. Abrams J. Mechanisms of action of the organic nitrates in the treatment of myocardial ischemia. Am. J. Cardiol. 70 (1992) 30B-42B
75. Tozer G.M., and Shaffi K.M. The response of tumour vasculature to angiotensin II revealed by its systemic and local administration to 'tissue-isolated' tumours. Br. J. Cancer 72 (1995) 595-600
76. Shan S.Q., Rosner G.L., Braun R.D., Hahn J., Pearce C., and Dewhirst M.W. Effects of diethylamine/nitric oxide on blood perfusion and oxygenation in the R3230Ac mammary carcinoma. Br. J. Cancer 76 (1997) 429-437
77. Jordan B.F., Misson P., Demeure R., Baudelet C., Beghein N., and Gallez B. Changes in tumor oxygenation/perfusion induced by the no donor, isosorbide dinitrate, in comparison with carbogen: monitoring by EPR and MRI. Int. J. Radiat. Oncol. Biol. Phys. 48 (2000) 565-570
78. Sonveaux P., Dessy C., Brouet A., Jordan B.F., Gregoire V., Gallez B., Balligand J.L., and Feron O. Modulation of the tumor vasculature functionality by ionizing radiation accounts for tumor radiosensitization and promotes gene delivery. FASEB J. 16 (2002) 1979-1981
79. Janssens M.Y., Van den Berge D.L., Verovski V.N., Monsaert C., and Storme G.A. Activation of inducible nitric oxide synthase results in nitric oxide-mediated radiosensitization of hypoxic EMT-6 tumor cells. Cancer Res. 58 (1998) 5646-5648
80. Kirkwood J.M., Bender C., Agarwala S., Tarhini A., Shipe-Spotloe J., Smelko B., Donnelly S., and Stover L. Mechanisms and management of toxicities associated with high-dose interferon alfa-2b therapy. J. Clin. Oncol. 20 (2002) 3703-3718
81. Wang Z., Cook T., Alber S., Liu K., Kovesdi I., Watkins S.K., Vodovotz Y., Billiar T.R., and Blumberg D. Adenoviral gene transfer of the human inducible nitric oxide synthase gene enhances the radiation response of human colorectal cancer associated with alterations in tumor vascularity. Cancer Res. 64 (2004) 1386-1395
82. Palmer L.A., Gaston B., and Johns R.A. Normoxic stabilization of hypoxia-inducible factor-1 expression and activity: redox-dependent effect of nitrogen oxides. Mol. Pharmacol. 58 (2000) 1197-1203
83. Sandau K.B., Faus H.G., and Brune B. Induction of hypoxia-inducible-factor 1 by nitric oxide is mediated via the PI 3K pathway. Biochem. Biophys. Res. Commun. 278 (2000) 263-267
84. Sandau K.B., Fandrey J., and Brune B. Accumulation of HIF-1alpha under the influence of nitric oxide. Blood 97 (2001) 1009-1015
85. Metzen E., Zhou J., Jelkmann W., Fandrey J., and Brune B. Nitric oxide impairs normoxic degradation of HIF-1alpha by inhibition of prolyl hydroxylases. Mol. Biol. Cell 14 (2003) 3470-3481
86. Sogawa K., Numayama-Tsuruta K., Ema M., Abe M., Abe H., and Fujii-Kuriyama Y. Inhibition of hypoxia-inducible factor 1 activity by nitric oxide donors in hypoxia. Proc. Natl. Acad. Sci. USA 95 (1998) 7368-7373
87. Huang L.E., Willmore W.G., Gu J., Goldberg M.A., and Bunn H.F. Inhibition of hypoxia-inducible factor 1 activation by carbon monoxide and nitric oxide. Implications for oxygen sensing and signaling. J. Biol. Chem. 274 (1999) 9038-9044
88. Yin J.H., Yang D.I., Ku G., and Hsu C.Y. iNOS expression inhibits hypoxia-inducible factor-1 activity. Biochem. Biophys. Res. Commun. 279 (2000) 30-34
89. Agani F.H., Puchowicz M., Chavez J.C., Pichiule P., and LaManna J. Role of nitric oxide in the regulation of HIF-1alpha expression during hypoxia. Am. J. Physiol. Cell Physiol. 283 (2002) C178-C186
90. Kimura H., Ogura T., Kurashima Y., Weisz A., and Esumi H. Effects of nitric oxide donors on vascular endothelial growth factor gene induction. Biochem. Biophys. Res. Commun. 296 (2002) 976-982
91. Mateo J., Garcia-Lecea M., Cadenas S., Hernandez C., and Moncada S. Regulation of hypoxia-inducible factor-1alpha by nitric oxide through mitochondria-dependent and -independent pathways. Biochem. J. 376 (2003) 537-544
92. Moncada S., and Erusalimsky J.D. Does nitric oxide modulate mitochondrial energy generation and apoptosis?. Nat. Rev. Mol. Cell Biol. 3 (2002) 214-220
93. Hagen T., Taylor C.T., Lam F., and Moncada S. Redistribution of intracellular oxygen in hypoxia by nitric oxide: effect on HIF1alpha. Science 302 (2003) 1975-1978
94. Li F., Sonveaux P., Rabbani Z.N., Liu S., Yan B., Huang Q., Vujaskovic Z., Dewhirst M.W., and Li C.Y. Regulation of HIF-1alpha stability through S-nitrosylation. Mol. Cell 26 (2007) 63-74
95. Moeller B.J., Cao Y., Li C.Y., and Dewhirst M.W. Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: role of reoxygenation, free radicals, and stress granules. Cancer Cell 5 (2004) 429-441
96. Moeller B.J., Dreher M.R., Rabbani Z.N., Schroeder T., Cao Y., Li C.Y., and Dewhirst M.W. Pleiotropic effects of HIF-1 blockade on tumor radiosensitivity. Cancer Cell 8 (2005) 99-110
97. Zhang X., Kon T., Wang H., Li F., Huang Q., Rabbani Z.N., Kirkpatrick J.P., Vujaskovic Z., Dewhirst M.W., and Li C.Y. Enhancement of hypoxia-induced tumor cell death in vitro and radiation therapy in vivo by use of small interfering RNA targeted to hypoxia-inducible factor-1alpha. Cancer Res. 64 (2004) 8139-8142
98. Williams K.J., Telfer B.A., Xenaki D., Sheridan M.R., Desbaillets I., Peters H.J., Honess D., Harris A.L., Dachs G.U., van der Kogel A., and Stratford I.J. Enhanced response to radiotherapy in tumours deficient in the function of hypoxia-inducible factor-1. Radiother. Oncol. 75 (2005) 89-98
99. Geng L., Donnelly E., McMahon G., Lin P.C., Sierra-Rivera E., Oshinka H., and Hallahan D.E. Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy. Cancer Res. 61 (2001) 2413-2419
100. Kozin S.V., Boucher Y., Hicklin D.J., Bohlen P., Jain R.K., and Suit H.D. Vascular endothelial growth factor receptor-2-blocking antibody potentiates radiation-induced long-term control of human tumor xenografts. Cancer Res. 61 (2001) 39-44
101. Ning S., Laird D., Cherrington J.M., and Knox S.J. The antiangiogenic agents SU5416 and SU6668 increase the antitumor effects of fractionated irradiation. Radiat. Res. 157 (2002) 45-51
102. Moeller B.J., Richardson R.A., and Dewhirst M.W. Hypoxia and radiotherapy: opportunities for improved outcomes in cancer treatment. Cancer Metastasis Rev. 26 (2007) 241-248
103. Messmer U.K., Ankarcrona M., Nicotera P., and Brune B. p53 expression in nitric oxide-induced apoptosis. FEBS Lett. 355 (1994) 23-26
104. Albina J.E., Cui S., Mateo R.B., and Reichner J.S. Nitric oxide-mediated apoptosis in murine peritoneal macrophages. J. Immunol. 150 (1993) 5080-5085
105. Sarih M., Souvannavong V., and Adam A. Nitric oxide synthase induces macrophage death by apoptosis. Biochem. Biophys. Res. Commun. 191 (1993) 503-508
106. Brune B., von Knethen A., and Sandau K.B. Transcription factors p53 and HIF-1alpha as targets of nitric oxide. Cell. Signal. 13 (2001) 525-533
107. Soler M.N., Bobe P., Benihoud K., Lemaire G., Roos B.A., and Lausson S. Gene therapy of rat medullary thyroid cancer by naked nitric oxide synthase II DNA injection. J. Gene Med. 2 (2000) 344-352
108. Worthington J., Robson T., O'Keeffe M., and Hirst D.G. Tumour cell radiosensitization using constitutive (CMV) and radiation inducible (WAF1) promoters to drive the iNOS gene: a novel suicide gene therapy. Gene Ther. 9 (2002) 263-269
109. Worthington J., McCarthy H.O., Barrett E., Adams C., Robson T., and Hirst D.G. Use of the radiation-inducible WAF1 promoter to drive iNOS gene therapy as a novel anti-cancer treatment. J. Gene Med. 6 (2004) 673-680
110. Le X., Wei D., Huang S., Lancaster Jr. J.R., and Xie K. Nitric oxide synthase II suppresses the growth and metastasis of human cancer regardless of its up-regulation of protumor factors. Proc. Natl. Acad. Sci. USA 102 (2005) 8758-8763
111. R.L. Cowen, S. Singh, E.C. Chinje, R. Al-Assah, P. Harris, C. Dunk, I.J. Stratford, Adenoviral delivery of inducible nitric oxide synthase (NOSII) enhances AQ4N/radiation cytotoxicity within hypoxic tumor cells, AACR Meeting Abstracts, 2005 (2005) 314-a.
112. Cowen R.L., Williams K.J., Chinje E.C., Jaffar M., Sheppard F.C., Telfer B.A., Wind N.S., and Stratford I.J. Hypoxia targeted gene therapy to increase the efficacy of tirapazamine as an adjuvant to radiotherapy: reversing tumor radioresistance and effecting cure. Cancer Res. 64 (2004) 1396-1402